Alessandro Tafuri1,2, Akbar N Ashrafi1, Suzanne Palmer3, Aliasger Shakir1, Giovanni E Cacciamani1, Atsuko Iwata1, Tsuyoshi Iwata1, Jie Cai1, Akash Sali1,4, Chhavi Gupta1,4, Luis G Medina1, Mariana C Stern1,5, Vinay Duddalwar3, Manju Aron4, Inderbir S Gill1, Andre Abreu6,7. 1. USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 2. Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. 3. Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 4. Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 5. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 6. USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Andre.Abreu@med.usc.edu. 7. USC Institute of Urology, Keck School of Medicine, University of Southern California, 1441 Eastlake Ave, Suite 7416, Los Angeles, CA, 90089, USA. Andre.Abreu@med.usc.edu.
Abstract
PURPOSE: To assess the feasibility, safety, and outcomes of an expedited One-Stop prostate cancer (PCa) diagnostic pathway. PATIENTS AND METHODS: We identified 370 consecutive patients who underwent multiparametric magnetic resonance imaging (mpMRI) and transrectal ultrasound fusion prostate biopsy (MRI/TRUS-PBx) from our institutional review board-approved database. Patients were divided according to diagnostic pathway: One-Stop (n = 74), with mpMRI and same-day PBx, or Standard (n = 296), with mpMRI followed by a second visit for PBx. mpMRIs were performed and interpreted according to Prostate Imaging-Reporting and Data System (PI-RADS v2). Grade group ≥ 2 PCa defined clinically significant PCa (csPCa). Statistical significance was considered when p < 0.05. RESULTS: Age (66 vs 66 years, p = 0.59) and PSA density (0.1 vs 0.1 ng/mL2, p = 0.26) were not different between One-Stop vs Standard pathway, respectively. One-Stop patients lived further away from the hospital than Standard patients (163 vs 31 km; p < 0.01), and experienced shorter time from mpMRI to PBx (0 vs 7 days; p < 0.01). The number (p = 0.56) and distribution of PI-RADS lesions (p = 0.67) were not different between the groups. All procedures were completed successfully with similar perioperative complications rate (p = 0.24). For patients with PI-RADS 3-5 lesions, the csPCa detection rate (49% vs 41%, p = 0.55) was similar for One-Stop vs Standard, respectively. The negative predictive value of mpMRI (PI-RADS 1-2) for csPCa was 78% for One-Stop vs 83% for Standard (p = 0.99). On multivariate analysis, age, prostate volume and PI-RADS score (p < 0.01), but not diagnostic pathway, predicted csPCa detection. CONCLUSION: A One-Stop PCa diagnostic pathway is feasible, safe, and provides similar outcomes in a shorter time compared to the Standard two-visit diagnostic pathway.
PURPOSE: To assess the feasibility, safety, and outcomes of an expedited One-Stop prostate cancer (PCa) diagnostic pathway. PATIENTS AND METHODS: We identified 370 consecutive patients who underwent multiparametric magnetic resonance imaging (mpMRI) and transrectal ultrasound fusion prostate biopsy (MRI/TRUS-PBx) from our institutional review board-approved database. Patients were divided according to diagnostic pathway: One-Stop (n = 74), with mpMRI and same-day PBx, or Standard (n = 296), with mpMRI followed by a second visit for PBx. mpMRIs were performed and interpreted according to Prostate Imaging-Reporting and Data System (PI-RADS v2). Grade group ≥ 2 PCa defined clinically significant PCa (csPCa). Statistical significance was considered when p < 0.05. RESULTS:Age (66 vs 66 years, p = 0.59) and PSA density (0.1 vs 0.1 ng/mL2, p = 0.26) were not different between One-Stop vs Standard pathway, respectively. One-Stop patients lived further away from the hospital than Standard patients (163 vs 31 km; p < 0.01), and experienced shorter time from mpMRI to PBx (0 vs 7 days; p < 0.01). The number (p = 0.56) and distribution of PI-RADS lesions (p = 0.67) were not different between the groups. All procedures were completed successfully with similar perioperative complications rate (p = 0.24). For patients with PI-RADS 3-5 lesions, the csPCa detection rate (49% vs 41%, p = 0.55) was similar for One-Stop vs Standard, respectively. The negative predictive value of mpMRI (PI-RADS 1-2) for csPCa was 78% for One-Stop vs 83% for Standard (p = 0.99). On multivariate analysis, age, prostate volume and PI-RADS score (p < 0.01), but not diagnostic pathway, predicted csPCa detection. CONCLUSION: A One-Stop PCa diagnostic pathway is feasible, safe, and provides similar outcomes in a shorter time compared to the Standard two-visit diagnostic pathway.
Entities:
Keywords:
MRI; MRI fusion biopsy; One-Stop; Prostate biopsy; Prostate cancer
Authors: G Igor Pinkhasov; Yu-Kuan Lin; Ricardo Palmerola; Paul Smith; Frank Mahon; Matthew G Kaag; J Edward Dagen; Lewis E Harpster; Carl T Reese; Jay D Raman Journal: BJU Int Date: 2012-02-07 Impact factor: 5.588
Authors: Nicola Fossati; Martina Sofia Rossi; Vito Cucchiara; Giorgio Gandaglia; Paolo Dell'Oglio; Marco Moschini; Nazareno Suardi; Federico Dehò; Francesco Montorsi; Riccardo Schiavina; Alexandre Mottrie; Alberto Briganti Journal: Urol Oncol Date: 2016-12-13 Impact factor: 3.498
Authors: Jeremy P Grummet; Mahesha Weerakoon; Sean Huang; Nathan Lawrentschuk; Mark Frydenberg; Daniel A Moon; Mary O'Reilly; Declan Murphy Journal: BJU Int Date: 2014-02-19 Impact factor: 5.588
Authors: Michael A Liss; Behfar Ehdaie; Stacy Loeb; Maxwell V Meng; Jay D Raman; Vanessa Spears; Sean P Stroup Journal: J Urol Date: 2017-03-29 Impact factor: 7.450
Authors: Mariana Andozia Morini; Roberto Lodeiro Muller; Paulo César Barbosa de Castro Junior; Rafael José de Souza; Eliney Ferreira Faria Journal: World J Urol Date: 2018-03-16 Impact factor: 4.226
Authors: Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey Journal: Am J Surg Pathol Date: 2016-02 Impact factor: 6.394
Authors: Ilan J Safir; Salil Gabale; Samuel A David; Jonathan H Huang; Robert S Gerhard; Jeffrey Pearl; Charles A Lorentz; James Baumgardner; Christopher P Filson; Muta M Issa Journal: Urology Date: 2016-07-19 Impact factor: 2.649
Authors: Veeru Kasivisvanathan; Antti S Rannikko; Marcelo Borghi; Valeria Panebianco; Lance A Mynderse; Markku H Vaarala; Alberto Briganti; Lars Budäus; Giles Hellawell; Richard G Hindley; Monique J Roobol; Scott Eggener; Maneesh Ghei; Arnauld Villers; Franck Bladou; Geert M Villeirs; Jaspal Virdi; Silvan Boxler; Grégoire Robert; Paras B Singh; Wulphert Venderink; Boris A Hadaschik; Alain Ruffion; Jim C Hu; Daniel Margolis; Sébastien Crouzet; Laurence Klotz; Samir S Taneja; Peter Pinto; Inderbir Gill; Clare Allen; Francesco Giganti; Alex Freeman; Stephen Morris; Shonit Punwani; Norman R Williams; Chris Brew-Graves; Jonathan Deeks; Yemisi Takwoingi; Mark Emberton; Caroline M Moore Journal: N Engl J Med Date: 2018-03-18 Impact factor: 176.079
Authors: Sam Watts; Geraldine Leydon; Brian Birch; Philip Prescott; Lily Lai; Susan Eardley; George Lewith Journal: BMJ Open Date: 2014-03-13 Impact factor: 2.692
Authors: Richard C Wu; Amir H Lebastchi; Boris A Hadaschik; Mark Emberton; Caroline Moore; Pilar Laguna; Jurgen J Fütterer; Arvin K George Journal: World J Urol Date: 2021-01-04 Impact factor: 4.226
Authors: Masatomo Kaneko; Dordaneh Sugano; Amir H Lebastchi; Vinay Duddalwar; Jamal Nabhani; Christopher Haiman; Inderbir S Gill; Giovanni E Cacciamani; Andre Luis Abreu Journal: Curr Urol Rep Date: 2021-03-22 Impact factor: 3.092
Authors: Dordaneh Sugano; Masatomo Kaneko; Wesley Yip; Amir H Lebastchi; Giovanni E Cacciamani; Andre Luis Abreu Journal: Cancers (Basel) Date: 2021-03-22 Impact factor: 6.639
Authors: George N Okoli; Otto L T Lam; Viraj K Reddy; Leslie Copstein; Nicole Askin; Anubha Prashad; Jennifer Stiff; Satya Rashi Khare; Robyn Leonard; Wasifa Zarin; Andrea C Tricco; Ahmed M Abou-Setta Journal: BMJ Open Date: 2021-11-09 Impact factor: 2.692